RNA chemical changes linked to tau in Alzheimer's brain

Epitranscriptomic Mechanism in pathogenesis of Alzheimer’s disease

NIH-funded research University of Virginia · NIH-11248429

This project looks at whether chemical tags on RNA in brain cells help cause the tau clumps that damage brains in Alzheimer's disease.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Virginia NIH-funded
Lab location1 site (Charlottesville, United States)
Project IDNIH-11248429 on NIH RePORTER

What this research studies

Researchers will examine human Alzheimer's brain tissue and lab models to see how patterns of RNA methylation change where tau proteins aggregate. They will measure RNA chemical tags, protein synthesis, and signs of neuron stress in post-mortem samples and in cell and 3‑D model systems. The team will test whether increased cytoplasmic RNA methylation coincides with stalled protein production and neuronal toxicity tied to tau. Results will be used to identify molecular steps that might be targeted to prevent or slow neuron loss.

Who could benefit from this research

Good fit: People with Alzheimer's disease or mild cognitive impairment, and families willing to donate brain tissue or join related biomarker studies, would be most relevant to this work.

Not a fit: People whose cognitive decline is caused by non‑Alzheimer conditions or by disease mechanisms unrelated to tau or RNA modifications may not receive direct benefit.

Why it matters

Potential benefit: If successful, this work could reveal new molecular targets to slow or stop tau-driven brain cell damage and guide the development of disease-modifying treatments for Alzheimer's.

How similar studies have performed: Prior studies have reported disrupted RNA metabolism and reduced protein synthesis in Alzheimer's brains, but directly linking RNA methylation to tau toxicity is a newer and less-tested idea.

Where this research is happening

Charlottesville, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Alzheimer disease dementia
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.